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1. Introduction
Cancer constitutes a major problem in animal pathology and is a subject of intensive research.
Canine mammary tumors are common neoplasms and have been reported to account for up
to half of all tumors in female dog [1]. All malignant canine mammary tumors have the
potential to metastasize and in general, metastasis tends to occur via the lymphatic system to
the inguinal lymph nodes or hematogenously to the lungs or to more distant body sites
including the liver, spleen, heart, bone [2]. Canine mammary tumors share many similarities
with breast cancer in human beings, including the high prevalence of adenocarcinomas,
frequency of metastasis and progressive disease [1].
Inflammatory mammary carcinoma is a special type of locally advanced mammary cancer that
is associated with particularly aggressive behaviour and poor prognosis in women - in which
case it is termed inflammatory breast carcinoma (IBC), and in the dog - in which case it is termed
inflammatory mammary carcinoma (IMC) [3-8]. In both species, this uncommon type of
tumors corresponds to a locally invasive mammary cancer that can be clinically misdiagnosed
as a dermatitis or mastitis owing to its special inflammatory phenotype [9,10]. Although the
pathogenesis of the disease remains obscure, some special clinical, genetic, biologic and
hormonal characteristics have been found to be specific for inflammatory breast carcinoma
and inflammatory mammary carcinoma [9,11-13].
Inflammatory mammary carcinoma is a very specific type of rare, very aggressive and highly
metastatic mammary cancer in dogs [7,8]. Clinical features include the presence of pain,
erythema, edema and ulceration in the skin of the mammary gland region. These features are
similar to symptoms of inflammatory diseases such as mastitis and dermatitis [2,7,8]. Histo‐
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logically there is evidence of a poorly differentiated carcinoma with extensive evidence of both
mononuclear and polymorphonuclear cellular infiltrates and often edema. Dermal lymphatic
invasion also can be seen histologically. Clinically, these neoplasms grow and metastasize
extremely rapidly and invade lymphatics in the skin, resulting in marked edema and inflam‐
mation [14].
Two clinical forms of inflammatory mammary carcinoma have been described in women and
dogs [8,9,15-17]: primary and secondary. Primary inflammatory mammary carcinoma occurs
suddenly in dogs without previous detection of lesions of mammary tumors while the
secondary inflammatory mammary carcinoma accompanies mammary tumors [8]. Secondary
inflammatory mammary carcinoma is further classified into two types: postsurgical whenever
it develops after surgical excision of a previous mammary tumors, and non-postsurgical when
developing from a previous mammary tumor not surgically treated that leaded to inflamma‐
tory mammary carcinoma [9,18,19].
Figure 1. Inflammatory mammary carcinoma (IMC), Hematoxylin-eosin (H&E); Bar = 100µm.
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Inflammatory  mammary  carcinoma occurs  most  often  in  female  dogs,  but  it  can  strike
male dogs too. Most dogs that develop this form of reproductive cancer are females who
have never been spayed,  or  who were spayed after  they were two years old.  Hormone
therapy can also increase your female dog's  risk of  developing mammary cancer.  Spay‐
ing your  dog before  she  undergoes  her  first  reproductive  cycle  at  six  months  of  age  is
the  best  way  to  prevent  inflammatory  carcinoma.  Rarely,  this  type  of  cancer  occurs  in
male dogs,  which also have mammary glands.  Dogs who develop a mammary carcino‐
ma  will  have  one  or  more  tumors  in  their  mammary  glands.  More  than  half  of  dogs
with this  type of  cancer  develop tumors  in  more than one mammary gland.  Malignant
tumors  grow  quickly,  are  often  irregular  in  shape,  may  attach  themselves  to  the  sur‐
rounding skin or tissue, and may cause painful inflammation and even ulceration of the
affected area [8,12,13,20,21].
Inflammatory mammary carcinoma in dogs often causes pain and swelling in the affect‐
ed area. The tumors may be hard or soft.  You will  be able to feel them under the skin,
and often they may be visible to the naked eye as well. The area will be warm and ten‐
der to the touch. It  is advised to take tissue biopsies of the tumors to determine if  they
are  cancerous  and  if  they  are  inflammatory  carcinoma.  Blood  tests  and  urinalysis  can
help the practitioner to determine if the cancer has spread, and how it may be affecting
other body organs [22].
Surgery is sometimes used to remove inflammatory carcinoma tumors, though this is not
always advisable in dogs. If the cancer has not yet spread, or if ulceration and infection has
occurred, it may be indicated to remove the tumor and affected mammary gland surgically. If
the dog has not yet been spayed, your vet may want to perform this procedure as well.
Inflammatory mammary cancer in dogs is an aggressive disease that spreads rapidly, and
surgery alone often does little to slow or stop its progression [21,22].
The clinician may recommend chemotherapy and radiation therapy to treat your dog's cancer,
even if the cancer has not yet spread. The prognosis for inflammatory carcinoma in dogs will
depend upon the size of your dog's tumors at the time of diagnosis, and whether or not the
cancer has already spread to other parts of the body. Survival time after treatment can range
from nine months to two years. Prevent inflammatory carcinoma by having your dog spayed
before she is six months old. Dogs who are obese, or who eat diets high in beef and pork, are
at an increased risk of developing inflammatory carcinoma [22].
In the clinical evaluation of inflammatory mammary carcinoma observed a strong resemblance
to the inflammatory process, so it is often confused with dermatitis [23-25]. Construction of
histological inflammatory mammary carcinoma is not uniform - they can be all forms of cancer
(Figure 2). Often these are tumors of low maturity. The lymphatic vessels of the skin congestion
states of cancer cells. The prognosis is bad.
The purpose of  this  study was to evaluate of  proliferating cell  nuclear antigen (PCNA),
cytokeratin 19 (CK19), and progesterone receptor (PgR) in two cases of canine inflamma‐
tory  mammary carcinoma and whether  or  not  these  markers  might  be  useful  in  tumor
identification or prognosis.
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Figure 2. Inflammatory mammary carcinoma (IMC), Hematoxylin-eosin (H&E); Bar = 100µm.
2. Materials and methods
2.1. Materials
A  total  of  135  samples  from  canine  mammary  tumours  were  used  in  this  study,  from
which  80  were  parafine-embeded archive  samples  from a  period  running  from 2006  to
2008,  and  55  were  fresh  samples  obtained  from  mastectomy  surgery,  performed  at
Warsaw Veterinary  Clinics  and  Small  Animal  Clinic  of  the  Department  of  Clinical  Sci‐
ences,  Faculty  of  Veterinary  Medicine,  Warsaw  University  of  Life  Sciences  –  SGGW.
Through  three  years  period,  only  two  cases  of  inflammatory  mammary  carcinoma
(IMC) were diagnosed,  which were further  confirmed by clinical  signs and histopathol‐
ogy  were  selected  for  further  immunohistochemical  studies.Investigated  material  con‐
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tained  14  adenomas,  66  complex  carcinomas  (adenocarcinomas),  47  simple  carcinomas
(adenocarcinomas),  6  solid  carcinomas and 2  inflammatory mammary carcinoma (IMC).
The  number  of  cancers  with  a  defined grade  amounted to,  respectively,  1st  grade  –  48,
2nd  grade  –  39  and  3rd  grade  –  34.  Mammary  gland  neoplasms  were  excised  from  fe‐
male  dogs  belonging  to  9  breeds  in  the  ages  between  3  and  16  years.  There  were  106
mixed-breed  dogs,  10  German  Shepherd  Dogs,  5  Boxers,  3,  Rottweilers,  2  Beagles,  6
Yorkshire  Terrier  and  1  each  of  the  following  breed:  English  Springer  Spaniel,  Labra‐
dor Retriever,  Doberman Pinscher.
2.2. Methods
Specimens were fixed in 8% buffered formalin, dehydrated and embedded in paraffin. 4μm
thick sections were cut from each mammary neoplasm. The sections were mounted onto slides
coated with 3-amino-propyltrietoxysilane (Sigma), deparaffinized in xylene and rehydrated
in graded ethanol concentrations. Antigen retrieval was performed in 10mM citrate buffer in
a microwave oven at 600W for 5 minutes and 300W for 10 minutes. The slides were left to cool
at room temperature immersed in the buffer. Thereafter they were washed for 10 minutes in
running tap water and rinsing in distilled water. Endogenous peroxidase was quenched by
immersion in a solution of 30% hydrogen peroxide and methanol (50 ml of H202 and 50 ml of
methanol) for 10 minutes. The slides were washed in distilled water then with TRIS (pH 7.4)
for 10 minutes, and then incubated with the primary monoclonal antibodies in humid chamber
for 1 hour at room temperature. Primary antibody clones and dilutions used for progesterone
receptor (PgR), proliferating cell nuclear antigen (PCNA), and for cytokeratin 19 (CK19)
presented (table 1).
Antibody Type Dilution AntigenRetrieval Incubation Source
Cytokeratin 19
(CK19) Mab * 1:50 HTAR ** 1 hr, room temp DakoCytomation
Progesterone
Receptor (PgR) Mab * 1:50 HTAR ** 1 hr, room temp Novocastra
Proliferating
cell nuclear
antigen (PCNA)
Mab * 1:50 HTAR ** 1 hr, room temp DakoCytomation
(*) Mab - mouse monoclonal antibody; (**) HTAR – high-temperature antigen retrieval (with 10 mM citrate buffer, pH
6.0).
Table 1. The antibodies used for immunohistochemistry
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The slides were washed in TRIS for 10 minutes. The EnVision +TM System (DakoCytomation)
was used for visualization. Visualization was achieved with 3,3’diaminobenzidine tetrahy‐
drocloride (DAB – DakoCytomation) in Tris-HCl buffer, and after rinsed slides were counter‐
stained with hematoxylin Ehrlicha, dehydrated in graded alcohol concentrations and xylene
and closed in DPX mounting medium (Gurr®).For progesterone receptor (PgR), proliferating
cell nuclear antigen (PCNA), and cytokeratin 19 (CK19), a canine mammary adenocarcinoma
was used as positive control. Computer image analysis and Lucia v. 4.21 software were used
for interpretation of the results of PCNA, CK19, PgR, expression; using those facilities we could
count the number of neoplastic cells featuring stained cytoplasm and nucleus per 1,000
neoplastic cells. Results were analyzed using the SPSS 12.0 program. To determine whether
differences for a few independent traits were significant, Kruskal-Wallis test was used. This
test is an equivalent to the test of variance for traits without normal distribution. Two-sided
correlations were performed using Spearman correlation test. The differences were deemed
statistically significant at p ≤ 0.05.
3. Results and discussion
3.1. Relationship between age of bitches and the grade of malignancy and histological type
of tumor of epithelial origin
Dogs  were  divided  into  three  age  groups:  <8  years,  8  -12  years  and  >12  years.  In  the
group of bitches below the age of 8,  majority (61.1%) consisted of tumors with the low‐
est histological grade of malignancy (1st). In the oldest group, 1st and 2nd grade tumors in
the  1st  and  2nd  accounted  for  77.8%.  In  the  entire  pool  of  studied  tumors  in  all  age
groups, the largest share consisted of tumors with the lowest degree of histological ma‐
lignancy (40.4%) (Table 2).  Assessment of the contribution of individual types of tumors
at different ages showed that in bitches younger than 8 years the most common findings
were adenomas (21.7%) and complex carcinomas (56.5%) and in those over 12 years sim‐
ple carcinomas occurred most often (55.0%) (Table 3).
Year of bitches
Tumor grade Total
Io IIo IIIo
<8 lat (n=18) 11 (61.1%) 3 (16.7%) 4 (22.2%) 18
8-12 lat (n=85) 30 (36.0%) 29 (35.0%) 26 (30.5%) 85
"/>12 (n=18) 7 (38.9%) 7 (38.9%) 4 (22.2%) 18
total (n=121) 48 (40.4%) 39 (32.8%) 34 (28.1%) 121
Table 2. Incidence of malignancies of various grades in bitches in different age groups
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Year of bitches
Types of tumors Total
Adenoma
Carcinoma
solidum
Adenocarcinoma
simplex
Adenocarcinoma
complex
Canine
inflammatory
mammary
carcinoma (IMC)
<8 lat 5 (21,7%) 1 (4,3%) 4 (17,4%) 13 (56,5%) 0 23
8-12 lat 7 (7,8%) 4 (4,4%) 32 (35,6%) 47 (52,2%) 2 (2.2%) 92
"/>12 lat 2 (10,0%) 1 (5,0%) 11 (55,0%) 6 (30,0%) 0 20
Total 14 (10,5%) 6 (4,5%) 47 (35,3%) 66 (49,6%) 2 (1.5%) 135
Table 3. Occurrence of individual types of epithelial neoplasms in different age groups in bitches
In our study, two inflammatory mammary carcinoma came from the dogs between the ages
of 8 and 9 years (case 1 - 8 year, case 2 - 9 year) (Table 2). These dogs had a clinically diagnosis
of IMC at the time of initial examination. The most important findings during physical
examination included: erythema and warmth, generalized induration of the involved mam‐
mary glands, cutaneous nodules affecting the overlying skin, edema of the proximal portion
of the hind limbs.
3.2. Results of proliferative activity in inflammatory mammary carcinoma
The value of mitotic index differed significantly between types of tumors. The lowest prolif‐
erative activity was observed in adenomas, the highest in simple carcinoma, solid carcinoma
and inflammatory mammary carcinoma. The highest proliferative activity was found in
tumors in the 3rd grade of malignancy, the lowest in the tumors in the 1st grade. Expression of
PCNA was observed in the nuclei of neoplastic cells that have undergone division (Figure 3).
Statistical analysis shows significant differences between particular types of tumors. The
lowest number of cells exhibiting PCNA expression was observed in adenomas, the highest
in the solid carcinoma, simple carcinoma, inflammatory mammary carcinoma and in tumors
with the highest histological grade of malignancy (3rd).
In the two cases canine inflammatory mammary carcinoma on the basis of H&E histopathology
found a high mitotic index (3.4 in the first case in the second case 4.1).PCNA index was similarly
and markedly elevated in the two animals: in case 1 inflammatory mammary carcinoma was
82%, in case 2 the inflammatory mammary carcinoma was 85% (Figure 3).
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Figure 3. Inflammatory mammary carcinoma – ICM, immunostaining for PCNA in a case of IMC; Bar=100µm
3.3. Results of cytokeratin 19 expression in inflammatory mammary carcinoma
Expression of cytokeratin 19 was observed in the neoplastic cell cytoplasm. Positive CK19
reaction was found in all tumors of epithelial origin. The high expression of CK19 was found
also in inflammatory mammary carcinoma (case 1 – intensity level of expression CK19 – 92%;
case 2 – intensity level of expression CK19 – 98%) (Figure 4 and 5).
3.4. Results of progesterone receptor expression in inflammatory mammary carcinoma
Progesterone receptor expression was detected in the nuclei of tumor cells, but it was also seen
in the cytoplasm. Cytoplasmic reaction was considered to be nonspecific. Among all tumors
of epithelial origin, expression of progesterone receptors was found in 56 (41.4%), and no
reaction was noted in 79 (58.5%). Expression of progesterone receptors was most commonly
found in complex cancers (43.9%), simple cancers (42.6%), adenomas (28.6%), while solid
cancers rarely expressed them (16.7%). The high expression of progesterone receptors was
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Figure 4. Inflammatory mammary carcinoma – ICM, immunostaining for cytokeratin 19 (CK19) in a case of IMC;
Bar=100 µm
Figure 5. Inflammatory mammary carcinoma – ICM, immunostaining for cytokeratin (CK19) in a case of IMC; Bar=50 µm
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found also in inflammatory mammary carcinoma 2 (100%) (Figure 6 and 7). Analysis of the
average number of cells showing positive expression of progesterone receptors reveals that
the level of expression increases with the histological grade of malignancy. It was also found
that most tumors expressing progesterone receptors came from dogs younger than 8 years. A
positive correlation was found between mitotic index and expression of progesterone receptors
in specific types of cancer and statistically significant differences between tumor characteristics
were demonstrated (p=0.042).
Figure 6. Inflammatory mammary carcinoma – ICM, nuclear expression of progesterone receptor (PgR); Bar=50 µm
Clinical signs and histopathological findings are necessary for the accurate diagnosis of
inflammatory mammary carcinoma. Our studies have suggested that inflammatory mammary
carcinoma is an aggressive malignancy because in our studies, the percentage of PCNA
positive cells within the tumor was high in the two cases. An important marker of malignancy
is the proliferative activity. Proper evaluation of proliferative activity of tumor cells is crucial
for the evaluation of its biological activity and is used in determining the treatment of cancer.
In our study, proliferative activity depended on both, the type of tumor and the degree of
histological malignancy. The highest values of mitotic index were recorded in simple carci‐
nomas, solid carcinomas and in two cases of inflammatory mammary carcinoma and in tumors
with the highest histological grade of malignancy. Similar results were reported for the
expression of PCNA. The highest expression of PCNA was seen in solid carcinomas, simple
carcinomas and in inflammatory mammary carcinoma and in 3rd grade tumors.
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Figure 7. Inflammatory mammary carcinoma – ICM, nuclear expression of progesterone receptor (PgR); Bar=100 µm
In our studies among all tumors of epithelial origin, expression of progesterone receptors was
found in 41.4%. Amorim et al. (2008) in their study found no expression of PgR in 9 cases
inflammatory mammary carcinoma [26]. However, Pen et al. (2003) found in their study high
positive immune reaction to PgR in inflammatory mammary carcinoma [12]. The high positive
immune reaction to PgR in canine inflammatory mammary carcinoma suggests,the possible
involvement of special endocrine mechanisms in inflammatory mammary carcinoma devel‐
opment.
During the three years in the research material collected was diagnosed only two cases of
canine inflammatory mammary carcinoma, therefore it can be said that canine inflammatory
mammary carcinoma is a rare cancer in dogs [8]. Perez et al. showed that inflammatory
mammary carcinoma is rare in dogs (17,7% of all cases within 4 years) [8]. Yet Susaneck et al.
[13] claimed that the incidence of canine inflammatory mammary carcinoma has doubled in
the past 15 years [7]. Pena et al. [12,13] in their research work diagnosed 33 of canine inflam‐
matory mammary carcinoma cases in a 5 years period.
All these authors described this type of cancer as a rare, unusual and different. Authors
investigated the relationship between clinical and histopathological characteristics of canine
inflammatory mammary carcinoma specifying nuclear antigen expression of PCNA, and
expression of progesterone receptor [7,8,12,13].
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4. Conclusion
Based on the literature and our own experience it can be concluded that canine inflammatory
mammary carcinoma is a rare tumors with poor prognosis. Our research suggests that
inflammatory mammary carcinoma is an aggressive malignancy, with a tendency to metasta‐
size at an early stage.
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